TAM
YMAB

Tiverton Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Tiverton Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$91K Sell
3,501
-1,437
-29% -$36.7K ﹤0.01% 651
2019
Q2 		$113K Sell
4,938
-3,400
-41% -$78.1K ﹤0.01% 609
2019
Q1 		$219K Hold
8,338
– – 0.01% 515
2018
Q4 		$170K Sell
8,338
-4,742
-36% -$109K 0.01% 324
2018
Q3 		$348K Buy
+13,080
New +$333K 0.02% 280

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tiverton Asset Management's YMAB Position: Q3 2019 in Review

Tiverton Asset Management reduced its Y-mAbs Therapeutics (YMAB) stake by 29% in Q3 2019, selling an estimated $36.7K and leaving 3,501 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #651.

Tiverton Asset Management first reported a position in YMAB in Q3 2018 and has held it in 5 quarters since. The position peaked at $348K in Q3 2018. 65 funds tracked by Wall St. Rank hold YMAB as of Q3 2019.

  • Tiverton Asset Management held 3,501 shares of Y-mAbs Therapeutics worth $91K as of Q3 2019.
  • Tiverton Asset Management sold 1,437 Y-mAbs Therapeutics shares in Q3 2019, an estimated $36.7K.
  • Y-mAbs Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #651 holding.
  • Tiverton Asset Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and has held it in 5 quarters since.
  • Tiverton Asset Management's Y-mAbs Therapeutics position peaked at $348K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.